The goal of this project is to conduct an impact assessment of ODIN, an Open Innovation in Science platform sponsored by the Novo Nordisk Foundation, where industry and academia co-create open research projects relevant for drug discovery and diagnostics. ODIN was established by five different universities together with a range of Danish and international companies within pharma and biotech.

CFA is responsible for an independent impact assessment of the ODIN platform, which in its current phase is in operation from 2024 to 2029.

CFA also conducted an impact assessment of the related ODIN pilot project (2020-2023).

For more information, see https://projects.au.dk/open-odin/impact.